Consultant Medical Oncologist & Honorary Senior Lecturer, UCL Cancer Institute
Mark carried out his CR-UK funded PhD with Professor Peter Parker at the London Research Institute (LRI, now the Francis Crick Institute), finishing in 2011. He continued his post doctoral research at the LRI while completing his oncology training at the Royal Marsden Hospital (RMH), leading to the appointment as a Consultant Medical Oncologist and Clinician Scientist on the Sarcoma Unit at the RMH. In June 2014, he was appointed as Consultant Medical Oncologist and NIHR/BRC Honorary Senior Lecturer at University College London (UCL) Hospital and UCL. Mark leads the Urological Cancer Biology Group as part of Prof Charlie Swanton’s Lab in the UCL-Cancer Institute. Mark’s specialist interests include the impact of genomic heterogeneity and kinase signalling on anti-cancer immunity. His laboratory and clinical activities have combined to help identify biomarkers that guide the drug discovery process. Mark has a patent and over 20 peer-reviewed papers including lead author papers in Science Signaling, Biochemical Journal and Carcinogenesis.